Vaxcyte (PCVX) Net Income towards Common Stockholders (2019 - 2026)

Vaxcyte (PCVX) has 8 years of Net Income towards Common Stockholders data on file, last reported at -$319.2 million in Q1 2026.

• Net Income towards Common Stockholders for Q1 2026 came in at -$319.2 million, down 115.91% year-over-year; the trailing twelve-month figure through Mar 2026 was -$975.3 million (down 89.53% YoY), and the FY2025 annual result was -$804.0 million, down 74.94% from the prior year.
• Net Income towards Common Stockholders slipped to -$319.2 million in Q1 2026 per PCVX's latest filing, from -$247.8 million in the prior quarter.
• Over five years, Net Income towards Common Stockholders peaked at $92.7 million in Q3 2023 and troughed at -$623.7 million in Q4 2023.
• A 5-year average of -$145.1 million and a median of -$111.9 million in 2024 frame the typical range for Net Income towards Common Stockholders.
• On a YoY basis, Net Income towards Common Stockholders climbed as much as 259.99% in 2023 and fell as far as 699.14% in 2023.
• A 5-year view of Net Income towards Common Stockholders shows it stood at -$78.0 million in 2022, then slumped by 699.14% to -$623.7 million in 2023, then surged by 79.85% to -$125.7 million in 2024, then sank by 97.14% to -$247.8 million in 2025, then decreased by 28.81% to -$319.2 million in 2026.
• Business Quant data shows PCVX's Net Income towards Common Stockholders at -$319.2 million in Q1 2026, -$247.8 million in Q4 2025, and -$213.1 million in Q3 2025.